[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-polyps\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-polyps":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,58,87,118,140,170,191,214,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100617125","recurrence-after-gastric-and-intestinal-polyp-resection-100617125",false,"NCT07314554","Recurrence After Gastric and Intestinal Polyp Resection","Recurrence Rate and Risk Factors After Endoscopic Resection of Gastric and Intestinal Polyps: A Retrospective and Prospective Cohort Study","RAGIP","Inclusion Criteria:\n\n* Age 18 years or older\n* First-time endoscopic examination (gastroscopy or colonoscopy) at the study center\n* Pathologically confirmed polyp of any type (adenomatous, hyperplastic, inflammatory, fundic gland polyp, hamartomatous, serrated lesion)\n* Complete endoscopic resection performed (including EMR, ESD, snare polypectomy, hot biopsy forceps, or argon plasma coagulation)\n* Negative resection margins or complete resection assessed by pathology\n* At least one follow-up endoscopic examination completed (for retrospective cohort) or willingness to complete follow-up (for prospective cohort)\n* Complete baseline clinical data available\n\nExclusion Criteria:\n\n* Hereditary polyposis syndromes (familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, juvenile polyposis syndrome)\n* Inflammatory bowel disease (ulcerative colitis or Crohn's disease)\n* Previous history of gastric or colorectal cancer\n* Cancer detected at initial resection (stage T1b or higher)\n* Non-polyp pathology (e.g., submucosal tumors, normal mucosa)\n* Incomplete resection with positive margins that were not re-treated\n* Lost to follow-up with no available surveillance data (for retrospective cohort)\n* Pregnancy at time of enrollment\n* Inability or unwillingness to provide informed consent (for prospective cohort)","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","3 Years","OBSERVATIONAL","This is a retrospective and prospective cohort study designed to evaluate the recurrence rate and identify risk factors after endoscopic resection of gastric and intestinal polyps.\n\nBACKGROUND: Gastric and intestinal polyps are common digestive diseases with potential for malignant transformation. Although endoscopic resection is the standard treatment, recurrence rates range from 10-50%, and the mechanisms and risk factors remain unclear.\n\nOBJECTIVES:\n\nPrimary: To assess short-term (1-year) and long-term (3-year) recurrence rates after endoscopic polyp resection Secondary: To identify independent risk factors and develop a recurrence risk prediction model\n\nDESIGN: Mixed retrospective-prospective cohort study\n\n* Retrospective cohort: Patients who underwent polyp resection from 2021-2022, with follow-up data through 2024\n* Prospective cohort: Patients enrolled from 2024-2025, with standardized follow-up through 2028\n\nSETTING: Single tertiary referral center with \\>10,000 endoscopic polyp resections performed since 2021\n\nPARTICIPANTS: Approximately 1,600-1,800 adult patients (≥18 years) who underwent complete endoscopic resection of gastric or intestinal polyps\n\nFOLLOW-UP:\n\n* Short-term: 1 year post-resection (±2 months)\n* Long-term: 3 years post-resection (±3 months)\n\nMAIN OUTCOME: Recurrence rate defined as new polyp detection at original or different sites during endoscopic surveillance\n\nPOTENTIAL RISK FACTORS: Patient demographics, polyp characteristics (size, number, location, pathology), resection method, Helicobacter pylori status, lifestyle factors, and medication use\n\nEXPECTED IMPACT: Results will inform personalized surveillance strategies and optimize resource allocation for post-polypectomy follow-up.",[26,27,28,29,30,31,32],"Gastric Polyps","Intestinal Polyps","Colon Polyps","Colorectal Polyps","Adenomatous Polyps","Gastric Adenoma and Early Gastric Cancer","Colorectal Adenoma",[34,35,36,37,38,39,40,41,42,43,44],"Polyp recurrence","Endoscopic resection","Polypectomy","Endoscopic mucosal resection","Endoscopic submucosal dissection","Risk factors","Surveillance","Follow-up","Adenoma","Gastric polyp","Colorectal polyp","NOT_YET_RECRUITING","2026-06-07",{"date":48,"type":49},"2026-06-09","ACTUAL",{"date":51,"type":21},"2026-07-26",{"date":53,"type":21},"2029-02-25",{"name":55,"class":56},"LanZhou University","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100627399","clinical-trial-to-evaluate-the-efficacy-and-safety-of-submo-as-a-submucosal-injection-agent-in-endoscopic-resection-of-superficial-gastrointestinal-lesions-100627399","NCT07448129","Clinical Trial to Evaluate the Efficacy and Safety of SUBMO® as a Submucosal Injection Agent in Endoscopic Resection of Superficial Gastrointestinal Lesions.","Randomized Clinical Trial to Evaluate the Efficacy and Safety of the Use of a Medical Device (SUBMO®) for Submucosal Injection in Endoscopic Resection Techniques of Superficial Gastrointestinal Lesions.","Inclusion Criteria:\n\n* Subjects \\>18 years old.\n* Presence of a colorectal lesion larger than 10 mm, confirmed through colonoscopy.\n* The lesion must be considered technically resectable using either Endoscopic Mucosal Resection (RME) or Endoscopic Submucosal Dissection (DSE).\n* The participant must be willing and able to comply with all required study visits and procedures, according to the protocol.\n* The participant must understand, sign, and date the written informed consent form before undergoing any study-specific procedures.\n\nExclusion Criteria:\n\n* Severe comorbidities according to clinical judgment, including patients classified as ASA IV or ASA V, except those ASA IV cases explicitly approved as clinically safe by the center's Anesthesiology Service (using the ASA anesthetic classification).\n* Patients presenting some coagulopathy that prevents safe endoscopic resection.\n* Lesions that are suspicious endoscopic invasive cancer.\n* Any medical condition that, in the investigator's opinion, could compromise patient safety or protocol adherence.\n* Known allergy or hypersensitivity to any component of the investigational product, including hyaluronic acid, methylene blue, or any excipients.\n* Contraindications to colonoscopy or to the administration of sedation\u002Fanesthesia.\n* Current participation in another clinical investigation with an investigational product, or participation in any clinical study (with tested or untested products) within the previous 30 days prior to randomization.\n* Pregnant or breastfeeding women.",{"count":66,"type":21},300,"INTERVENTIONAL",[69],"NA","The SUBMO-PIC01-2025 study evaluates whether SUBMO®, a submucosal injection hydrogel composed of high-molecular weight hyaluronic acid and methylene blue, is as effective and safe as normal saline for endoscopic resection of superficial colorectal lesions larger than 10 mm. Its primary aim is to determine non-inferiority in complete resection rates, whether en bloc or fragmented, and to assess safety through the systematic identification of serious adverse events. Secondary aims include analysing the total volume of product needed, the number of injections required, the maintenance of the submucosal cushion, the duration of the procedure, the ease of resection, the subjective evaluation of endoscopists, and the appearance of additional adverse events related to the intervention such as intraprocedural bleeding, fever, significant post-procedure pain, post-coagulation syndrome or immediate or delayed perforation.\n\nEligible participants are adults aged 18 or older with a confirmed colorectal lesion greater than 10 mm that is technically resectable using EMR or ESD, who are capable and willing to follow the study procedures and who have signed informed consent prior to any protocol-specific action. Exclusion criteria include severe comorbidities corresponding to ASA IV or V unless specifically authorised by anaesthesia, coagulopathies that prevent endoscopic resection, endoscopic suspicion of invasive cancer, any condition deemed by investigators to compromise safety or adherence, known allergy to hyaluronic acid, methylene blue or excipients, contraindications to colonoscopy or sedation, participation in another clinical investigation within the previous 30 days, and pregnancy or breastfeeding. Participants may be withdrawn due to voluntary consent withdrawal, safety concerns, protocol deviations that affect data integrity or patient safety, loss to follow-up or pregnancy discovered during the study.\n\nThe main efficacy variable is the technical success of resection as judged immediately by the endoscopist, while the main safety variable is the incidence of serious adverse events and their causal relationship with the investigational product. Exploratory variables include baseline demographics such as age, sex, ethnic origin and body mass index, anticoagulant or antiplatelet medication, and comorbidities including endoscopic history, obesity, hypertension, cardiovascular disease, haematologic disorders such as von Willebrand disease or haemophilia, and chronic liver disease. Baseline variables also include ASA classification and lifestyle habits. Polyp-related variables include size, number, anatomical location in the colon or rectum, LST subtype and JNET classification. Resection-related variables capture the technique used (EMR or ESD), whether the resection is en bloc or piecemeal, the number of fragments for calculating the Sydney Resection Quotient, the DMI score and any closure technique or complications. Treatment-related variables include total and per-surface area injection volume, number of submucosal injections needed, macroscopic evaluation of cushion maintenance, total procedure time, ease of resection using a visual analogue scale from 0 to 100, a usability questionnaire completed by the endoscopists and a detailed record of all adverse events including bleeding, fever, pain, post-coagulation syndrome and perforation.",[29],[73,74,75],"Submucosal injection","endoscopic resection","hyaluronic acid hydrogel","2026-03-03",{"date":78,"type":49},"2026-03-05",{"date":80,"type":21},"2026-03",{"date":82,"type":21},"2027-03",{"name":84,"class":85},"i+Med S.Coop.","INDUSTRY",4,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":57},"100625573","colo-predict-digital-training-and-optical-diagnosis-of-colorectal-polyps-100625573","NCT07424391","COLO-PREDICT: Digital Training and Optical Diagnosis of Colorectal Polyps","Impact of a Digital Training Program (Colo-ID) on Optical Histologic Prediction and Management of Colorectal Polyps: A Prospective Study","COLO-PREDICT","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Patients undergoing colonoscopy in routine clinical practice at the participating center\n* At least one colorectal polyp detected during colonoscopy\n* Optical histology prediction recorded during the procedure\n* Histopathological analysis available for resected polyps (reference standard)\n\nExclusion Criteria:\n\n* Patients aged \\\u003C18 years\n* Refusal\u002Fopposition to use of data (if applicable under local regulations)\n* Missing key study data (e.g., no recorded optical prediction or no histopathology result)",{"count":96,"type":21},1500,"Colorectal cancer prevention relies on high-quality colonoscopy and accurate optical characterization of colorectal polyps. Optical diagnosis may allow optimization of management strategies such as resect-and-discard for diminutive polyps, potentially improving efficiency in routine practice.\n\nCOLO-PREDICT is a prospective, single-center, observational study designed to evaluate the impact of a structured digital training program (Colo-ID, a digital application for colonic polyp characterisation training) on the accuracy of optical histology prediction of colorectal polyps in real-life clinical practice.\n\nAll consecutive adult patients undergoing colonoscopy with at least one detected polyp will be included. Optical prediction of polyp histology will be recorded during the procedure. All polyps will be resected and sent for histopathological analysis according to standard practice. No modification of patient management will occur as part of the study.\n\nThe primary objective is to assess the concordance between optical prediction and histopathology before and after implementation of the digital training program. Secondary objectives include evaluation of prediction performance according to polyp characteristics and assessment of potential implications for clinical practice.",[29],[100,101,102,103,104,105,106,107],"Optical diagnosis","Colonoscopy","Histologic prediction","Resect-and-discard strategy","Digital training","Endoscopic imaging","Polyp characterization","Real-world study","RECRUITING","2026-02-20",{"date":111,"type":49},"2026-02-23",{"date":113,"type":49},"2026-02-09",{"date":115,"type":21},"2026-09",{"name":117,"class":56},"Clinique Paris-Bercy",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":67,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100620815","ai-assisted-real-time-endoscopic-characterization-of-diminutive-colorectal-polyps-in-non-academic-hospitals-100620815","NCT07362524","AI-Assisted Real-Time Endoscopic Characterization of Diminutive Colorectal Polyps in Non-Academic Hospitals","Artificial Intelligence-assisted Optical Diagnosis for the Resect-and-discard Strategy in Clinical Practice in Non-academic Hospitals: a Randomized Controlled Study","Inclusion Criteria:\n\n1. Agree to participate in this prospective randomized controlled study;\n2. Age ≥18 years for colonoscopy;\n3. At least one colorectal diminutive polyp (size \\\u003C=5mm) found during examination;\n\nExclusion Criteria:\n\n1. Already participating in other clinical trials, having signed informed consent and being in the follow-up period of other clinical trials;\n2. Already participating in drug clinical trials and being in the washout period of experimental or control drugs;\n3. History of drug or alcohol abuse or psychological disorders in the past five years;\n4. Pregnant or lactating patients;\n5. Known polyposis syndromes;\n6. Patients with gastrointestinal bleeding;\n7. Previous history of inflammatory bowel disease, colorectal cancer, or colorectal surgery;\n8. Patients with contraindications to tissue biopsy;\n9. Previous history of allergic reactions to bowel cleansing agent components;\n10. Suffering from intestinal obstruction or perforation, toxic megacolon, heart failure (Grade III or IV), severe cardiovascular disease, severe liver failure, or renal insufficiency, etc.;\n11. Patient's bowel preparation BBPS score \\\u003C6 for this colonoscopy;\n12. Researchers consider the patient unsuitable for trial participation.",{"count":126,"type":21},363,[69],"To validate the feasibility of promoting colorectal diminutive polyp \"predict, resect, and discard\" and \"diagnose and leave\" strategies for non-experts in general hospitals through CADx system.",[29],"2026-01-15",{"date":132,"type":49},"2026-01-23",{"date":134,"type":21},"2026-02-15",{"date":136,"type":21},"2026-11-15",{"name":138,"class":56},"Shanghai Jiao Tong University School of Medicine",2,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":67,"phases":152,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100593362","accuracy-and-sustainability-of-scale-eye-evaluation-for-measuring-reliable-polyp-size-100593362","NCT07005453","Accuracy and Sustainability of SCALE-EYE Evaluation for Measuring Reliable Polyp Size","Diagnostic Performance and Sustainability of Using SCALE-EYE During Real-Time Colonoscopy","ASSEMBLE","Inclusion Criteria:\n\n* Participants aged 55-80\n* Scheduled for fecal immunochemical test (FIT) screening or surveillance colonoscopy\n* Polyps of all forms ≤25 mm as assessed by the endoscopist\n\nExclusion Criteria:\n\n* No detected colorectal polyps or only diminutive (≤5 mm) hyperplastic rectal polyps are present\n* Inadequate bowel preparation (Boston Bowel Preparation Score (BBPS) \\\u003C2 per segment)\n* Intraprocedural complications, not caused by the study device\n* Known or suspected inflammatory bowel disease (IBD)\n* Polyposis syndromes (e.g. serrated polyposis, familial adenomatous polyposis)\n* Ileoanal pouch and anastomosis\n* History of radiation or chemotherapy for colorectal lesions\n* Scheduled for therapeutic procedure (for example intervention to stop a lower gastro-intestinal bleeding, endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD))\n* Pregnancy\n* No Informed consent (IC) possible","55 Years","80 Years",{"count":151,"type":21},241,[69],"A multicenter, randomized, parallel group, endoscopist blinded study to assess the diagnostic performance and sustainability of SCALE-EYE in a screening and surveillance colonoscopy population.\n\nSustainability will be evaluated in terms of the reduction in colonoscopies, associated waste and carbon footprint.",[29],[156,157,158,159],"virtual scale endoscopy","biopsy forceps","optical assessment","colorectal cancer","2026-01-12",{"date":162,"type":49},"2026-01-13",{"date":164,"type":49},"2025-09-23",{"date":166,"type":21},"2026-04-01",{"name":168,"class":56},"Erasmus Medical Center",3,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":149,"enrollmentInfo":177,"targetDuration":4,"studyType":67,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":57},"100588104","efficacy-and-safety-of-cold-versus-hot-snare-polypectomy-for-removal-of-4-10-mm-pedunculated-colorectal-polyps-100588104","NCT06937047","Efficacy and Safety of Cold Versus Hot Snare Polypectomy for Removal of 4-10 mm Pedunculated Colorectal Polyps","Efficacy and Safety of Cold Versus Hot Snare Polypectomy for Removal of 4-10 mm Pedunculated Colorectal Polyps: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. 18-80 years old, male and female\n2. Proposed colonoscopy and colonoscopy detection of at least one 4-10 mm pedunculated colorectal polyp\n\nExclusion Criteria:\n\n1. Contraindication to colonoscopy or polypectomy\n2. Use of antiplatelet or anticoagulant drugs within 1 week before polypectomy\n3. Alarming signs and symptoms of colorectal cancer (blood in stool, black stool, unexplained anaemia and weight loss, abdominal mass, positive rectal examination; or imaging and laboratory tests highly suspicious for colorectal cancer) or endoscopic manifestations of polyps highly suspicious for high-grade intraepithelial neoplasia or carcinoma\n4. Comorbidity with inflammatory bowel disease, colonic polyposis, or active gastrointestinal bleeding\n5. Inadequate bowel preparation\n6. Pregnant or lactating women\n7. Failure to sign the informed consent form\n8. Patients deemed ineligible by investigators to enrol in the trial",{"count":178,"type":21},196,[69],"This was a non-inferiority randomized controlled trial designed to compare the efficacy and safety of cold versus hot snare polypectomy for the removal of 4-10 mm pedunculated colorectal polyps. The primary outcome was delayed postpolypectomy bleeding. The secondary outcomes included immediate postpolypectomy bleeding, procedure time, en bloc resection, complete histologic resection, use of haemostatic clips and perforation rate.",[29],"2025-04-27",{"date":184,"type":49},"2025-04-29",{"date":186,"type":21},"2025-05-06",{"date":188,"type":21},"2027-02-28",{"name":190,"class":56},"Shandong University",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":198,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":67,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100587138","advanced-adenoma-detection-with-3d-imaging-device-during-colonoscopy-100587138","NCT06924489","Advanced Adenoma Detection With 3D Imaging Device During Colonoscopy","Effect of 3-Dimensional Imaging Device on Advanced Adenoma Detection During Colonoscopy: A Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18-75 years;\n* Patients with indications for colonoscopy and receiving diagnostic colonoscopy, without history of inflammatory bowel disease, colorectal cancer, polypectomy or polyposis syndromes;\n* Signing the written informed consent;\n\nExclusion Criteria:\n\n* Patients with polyposis syndromes (e.g., Peutz-Jeghers syndrome, Cronkhite-Canada syndrome, familial adenomatous polyposis \\[FAP\\], Lynch syndrome, etc.);\n* Patients with a history of colorectal polypectomy and pathological diagnosed as adenoma;\n* Patients with a history of colorectal adenocarcinoma or alarming symptoms;\n* Patients with a history of inflammatory bowel disease;\n* Patients with mental illness or severe functional disorder who cannot cooperate with colonoscopy;\n* Patients with severe cardiopulmonary insufficiency;\n* Patients with severe coagulation disorders or high bleeding risk (platelets \\\u003C50×10⁹\u002FL, INR \\>1.5; discontinuation of antithrombotic drugs should follow the 2012 Japanese Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment and the2017 Appendix on Anticoagulants Including Direct Oral Anticoagulants;\n* Patients with severe electrolyte imbalances;\n* Patients with acute peritonitis or suspected intestinal perforation;\n* Patients with toxic megacolon;\n* Patients with stage 3 or higher hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg);\n* Patients with untreated severe abdominal hernia, intestinal obstruction;\n* Patients with intestinal strictures of any cause;\n* Pregnancy and lactation.",true,"75 Years",{"count":201,"type":21},1566,[69],"The goal of this clinical trial is to learn if 3-dimensional (3D) imaging device works to identify patients with high risk adenomas during colonoscopy to guide proper follow-up strategy. It will also learn about the safety of 3-dimensional (3D) imaging device. The main questions it aims to answer are:\n\nDoes 3-dimensional (3D) imaging device improve the identification of patients with high risk adenomas? What adverse events do participants experience during colonoscopy? Researchers will compare 3-dimensional (3D) imaging device to traditional 2-dimensional (2D) imaging device to see if 3-dimensional (3D) imaging device works to improve high risk adenoma identification.\n\nParticipants will:\n\nUndertake colonoscopy examination using 3-dimensional (3D) imaging device or 2-dimensional (2D) imaging device. Be followed-up to 30 days to record potential colonoscopy-relevant adverse events.",[32,29],"2025-04-04",{"date":207,"type":49},"2025-04-11",{"date":209,"type":21},"2025-06-01",{"date":211,"type":21},"2026-07-01",{"name":213,"class":56},"Xijing Hospital of Digestive Diseases",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":198,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":57},"100575557","ai-in-predicting-polyp-pathology-and-endoscopic-classification-100575557","NCT06773832","AI in Predicting Polyp Pathology and Endoscopic Classification","Artificial Intelligence Predicts the Pathology and Endoscopic Classification of Colorectal Polyps During Colonoscopy","Inclusion Criteria:\n\n1. Outpatients or inpatients undergoing routine colonoscopy screening at the endoscopy centers of multicenter hospitals;\n2. Aged 18 years or older;\n3. Have understanding of the study content and have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Gastroparesis or gastric outlet obstruction;\n2. Known or suspected intestinal obstruction or perforation;\n3. Severe chronic renal failure (creatinine clearance less than 30 mL\u002Fminute);\n4. Severe congestive heart failure (New York Heart Association Class III or IV);\n5. Currently pregnant or breastfeeding;\n6. Toxic colitis or megacolon;\n7. Poorly controlled hypertension (systolic blood pressure greater than 180 mmHg and\u002For diastolic blood pressure greater than 100 mmHg);\n8. Moderate or massive active gastrointestinal bleeding (\\>100 mL\u002Fday);\n9. Significant psychiatric or psychological illness;\n10. Allergy to medications used for bowel preparation;\n11. Patients who have undergone colorectal surgery.",{"count":222,"type":21},400,"Background: Colonoscopy with optical diagnosis based on the appearance of polyps can guide the selection of endoscopic treatment methods, reduce unnecessary polypectomy procedures and the need for tissue pathological diagnosis, and formulate follow-up strategies in a timely manner \\[1\\]. This approach significantly alleviates the economic burden on patients and the healthcare system and can effectively ease the tension on clinical resources \\[2\\]. Various endoscopic polyp classification methods, including Pit Pattern \\[3\\], NICE \\[4\\], WASP \\[5\\], and MS \\[6\\], are used to determine pathological types. However, mastering these classification methods requires endoscopists to undergo extensive training, and due to the inherent flaws in each method, no single endoscopic classification method can accurately diagnose all types of polyps to meet the requirements of optical diagnosis. This limitation has hindered the widespread application of optical diagnosis in clinical practice \\[7\\]. The application of artificial intelligence technology in this field, known as computer-aided diagnosis (CADx), has seen rapid development in recent years. Numerous large-scale, prospective studies have demonstrated that the accuracy of CADx technology for optical diagnosis of minute lesions (\\\u003C5mm) has essentially met the threshold set by European and American endoscopy societies for optical diagnosis \\[8,9\\]. However, the diagnostic efficacy of CADx for polyps ≥5mm remains unclear. Moreover, current research is mostly limited to distinguishing between common adenomas and hyperplastic polyps, with little attention given to serrated lesions, which are also precancerous lesions and progress even more rapidly, and are more challenging for endoscopists to assess. These reasons prevent CADx from being widely applied in clinical practice for real-time accurate judgment of polyp pathological types.",[29],[101,226,227,228,42],"Artificial Intelligence","Optical Diagnosis","Sessile Serrated Adenoma","2025-01-12",{"date":231,"type":49},"2025-01-14",{"date":233,"type":21},"2025-01",{"date":235,"type":21},"2026-12",{"name":237,"class":56},"Peking Union Medical College Hospital",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":57},"100564428","6-year-follow-up-data-after-the-berberine-intervention-trial-100564428","NCT06629051","6-year Follow-up Data After the Berberine Intervention Trial","A Multicenter, Placebo-controlled Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas：6-year Retrospective Follow-up Data","Inclusion Criteria: participants who completed the previous berberine intervention study (NCT02226185) Exclusion Criteria: no",{"count":246,"type":21},891,"Colorectal cancer (CRC) is a common malignancy of the digestive tract, which constitutes a major public health burden. Almost 90% of CRC cases progress from precursor adenomatous polyps through adenoma-carcinoma sequence. Endoscopic detection and removal of colorectal adenoma (CRA) could reduce the incidence and mortality risk of CRC, but the recurrence rate is still high. Therefore, chemoprevention is quite important, not only solve the urgent public health problem, but also be cost-effective.\n\nIn 2020, the investigators published a multicenter, randomized, double-blind, placebo-controlled clinical study (NCT02226185) in the Lancet Gastroenterology \\& Hepatology. The result concluded that oral BBR for 2 years significantly reduced recurrence after endoscopic removal of CRA (RR 0.77, 95%CI 0.66-0.91; p=0.001). BBR also has a significant preventive effect on all polypoid lesions, including adenomas and serrated lesions (adjusted RR 0.78, 95%CI 0.66-0.91; p=0.002) . Does BBR still have a long-term protective effect on the recurrence of CRA after discontinuation? That's what the investigators concerned.\n\nThe present study is performed to observe and compare retrospectively the recurrence rate of CRAs in patients of the original BBR RCT study (NCT02226185) within 6 years after discontinuation of medication, including the overall recurrence rate of traditional adenomas within the first year, 1-3 years, 3-6 years, and the entire follow-up period of 6 years. The aim is to evaluate the long-term efficacy of BBR in preventing recurrence and carcinogenesis after endoscopic resection of CRAs.",[32,249,29],"Colorectal Cancer Control and Prevention",[251,252,159,253,254],"berberine","colorectal adenoma","long term chemoprevention","colorectal polyps","2024-10-04",{"date":257,"type":49},"2024-10-08",{"date":255,"type":21},{"date":260,"type":21},"2024-12-31",{"name":138,"class":56}]